This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A C C E P T E D M
A N U S C R I P T
Introduction
Cryptosporidium species are intracellular protozoan parasites that infect a wide range of hosts including humans, domestic and wild animals (Ryan et al., 2014; Zahedi et al., 2016) . World-wide, human cryptosporidiosis is mainly caused by two species of Cryptosporidium (C. hominis and C. parvum); although numerous species of Cryptosporidium have been reported in humans, including C. meleagridis, C. felis, C. canis, C. cuniculus, C. ubiquitum, C. viatorum, C. suis, C. scrofarom, C. viatorum, C. tyzerri, C. xiaoi, C. fayeri, C. muris, and C. andersoni (Xiao, 2010; Ryan et al., 2016) .
Cryptosporidium infection can result in acute diarrhea, nausea, vomiting and weight loss, which is usually self-limiting . In infants, cryptosporidiosis can be more serious and can lead to malnutrition, growth retardation and impairment in cognitive function (Shrivastava et al., 2017) . Similarly, patients with some type of immunocompromised condition have an increased probability of acquiring cryptosporidiosis, which can manifest as severe protracted diarrhoea, chronic malabsorption, failure to thrive, malnutrition and increased mortality (Assefa et al., 2009; Idris et al., 2010; Domenech et al., 2011; Kurniawan et al., 2013; Marcos and Gotuzzo, 2013; Valenzuela et al., 2014; Nsagha et al., 2016) .
Immunosuppression and diarrhoea are well-recognised side-effects of cancer treatment, yet relatively few studies have been conducted examining the prevalence of Cryptosporidium in cancer patients (Botero et al., 2003; Tamer et al., 2008; Al-Qobati et al., 2012; Hassanein et al., 2012; Sulżyc-Bielicka et al., 2012; García-Elorriaga et al., 2013) . In Jordan, the molecular epidemiology of cryptosporidiosis is poorly understood and to date, only two genotyping studies have been conducted (Hijjawi et al., 2010; Hijjawi et al., 2016) . The aim of the present study was to investigate the prevalence of Cryptosporidium species and subtypes in paediatric oncology patients with diarrhoea and paediatric patients with diarrhoea only, to better understand the epidemiology
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Materials and methods

Cryptosporidium isolates
A total of 297 fresh diarrheic stool specimens were collected from two groups of children (aged 1-5 years old) from April until December, 2016; including paediatric oncology patients with diarrhoea at the King Hussein Medical Centre for Cancer (n=160) and paediatric patients with diarrhoea only at the Al-Mafraq paediatric hospital (n=137). The samples from King Hussein Medical Centre for Cancer were collected from children undergoing chemotherapy for different types of cancer (mainly leukemia) and who resided in different parts of Jordan but regularly visited the centre for treatment. The children who were referred to the Al-Mafraq paediatric hospital, were mainly from Al-Mafraq city and nearby villages. In addition, a further 30 samples were collected from the same two hospitals (18 samples from the King Hussein Medical Centre for Cancer and 12 from Al-Mafraq hospital), from children with diarrhoea, but which were negative by microscopy for Cryptosporidium oocysts, in order to serve as a negative control to compare the sensitivity of microscopy and PCR. 
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Microscopy, DNA extraction and typing
Microscopy was performed on all faecal samples using a routine modified acid fast staining procedure. Briefly, a smear was prepared using 1 to 2 drops of the collected stool specimen, fixed with absolute methanol for 30 seconds, stained with carbol fuchsin for 3 minutes, rinsed briefly with tap water before being stained with methylene blue. The stained dried slides were labelled and examined at 100x oil immersion lens under a light microscope (Olympus CH40/RF200, Japan) for the presence of Cryptosporidium oocysts.
For subsequent DNA extraction, 1 to 2 gm of the individually collected fresh stool specimen from each child were fixed in 2.5% potassium dichromate and left at room temperature for 2-6 months. Before DNA extraction, the stool samples were washed three times in 10% PBS buffer and centrifuged at 2000 x g for 2-3 minutes in order to remove the potassium dichromate. Total DNA was extracted using a QIAmp DNA Stool Kit (Qiagen, Germany), following the recommendation of the supplier after 5 cycles of freezing and thawing. The extracted DNA was stored at -80ºC until further molecular characterization. All samples which were positive for Cryptosporidium by microscopy (n=30) and the 30 samples that were Cryptosporidium negative by microscopy (negative controls) were initially screened at the 18S locus and identified to species level using nested PCR amplification and Sanger sequencing as previously described (Xiao et al., 1999) .
Samples were then subtyped at the glycoprotein 60 (gp60) locus using a nested PCR to amplify a ~400 bp product using the primers AL3531 (5'-ATAGTCTCCGCTGTATTC-3') and AL3533 (5-GAGATATATCTTGGTGCG-3) for the primary PCR, and AL3532 (5'-TCCGCTGTATTCTCAGCC-3') and LX0029 (5'-CGAACCACATTACAAATGAAGT-3') for the secondary PCR (Sulaiman et al., 2005) .
Statistical analysis
The prevalence of Cryptosporidium in faecal samples collected from each group was expressed as the percentage of samples positive by microscopy, with 95% confidence intervals calculated assuming a binomial distribution, using the software Quantitative Parasitology 3.0 (Rózsa et al., 2000) . Fisher's exact test was performed using SPSS 22 for Windows (SPSS Inc.
Chicago, USA), to determine if there was a statistical difference in the prevalence of Cryptosporidium in paediatric oncology patients with diarrhoea and paediatric patients with diarrhoea only.
Results
Prevalence by microscopy and demographic data
Microscopic screening using modified acid fast staining of the 297 stool specimens from the recruited children in the present study identified a prevalence of 14.4% (23/160) -95% CI 9.3-20.8, in paediatric oncology patients with diarrhoea and 5.1% (7/137) -95% CI, 2.1-10.2 for nononcology paediatric patients with diarrhoea. This difference was significant (p<0.05). The overall prevalence of Cryptosporidium across the two groups was 10.1% (30/297) 95% CI 6.9-14.1.
The majority of Cryptosporidium-positive paediatric oncology patients (82.6% -19/23) were experiencing diarrhoea, whereas the remaining 4 had soft stools (Table 1) . Of the paediatric patients from Al-Mafraq hospital, 57.1% (4/7) had diarrhoea, while the remaining 3 had soft stools (Table 2) . Leukemia was the most common type of cancer experienced by the patients that were
positive for Cryptosporidium (n=12), followed by lymphoma (n=2). Data on the type of cancer was unavailable for 6 patients (Table 1) .
Cryptosporidium species and gp60 subtypes
Sequences were obtained for 29/30 positives from the two groups. In addition, screening of the additional 30 faecal samples from paediatric patients from both hospitals, which were negative for Cryptosporidium by microscopy, identified another 3 positives. A total of 32 samples typed. All were identified as C. parvum. Of the 22 typed Cryptosporidium positives from the paediatric oncology patients, from King Hussein Medical Centre for Cancer, 21 were typed as IIaA17G2R1
and one as IIaA16G2R1 (Table 1 ). The 7 typed positives from the paediatric patients from AlMafraq hospital were typed as IIaA17G2R1 (n=5) and IIaA16G2R1 (n=2). The 3 additional positives from the 30 microscopy negative control samples were typed as IIaA17G2R1
(Supplementary Table 1 ). There was no heterogeneity within individual subtypes. Representative gp60 sequences from C. parvum subtypes IIaA17G2R1 and IIaA16G2R1 were submitted to GenBank under accession numbers MF770731 -MF770734.
Discussion
The present study compared the prevalence of Cryptosporidium species and gp60 subtypes among paediatric oncology and non-oncology patients with diarrhoea. As expected, the prevalence of Cryptosporidium was significantly higher amongst paediatric oncology patients with diarrhoea (14.4%), compared to non-oncology paediatric patients with diarrhea (5.1%), with 2.8 times more cryptosporidiosis cases amongst the former. This result is similar to a previous study in Egypt,
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A C C E P T E D M A N U S C R I P T 8 which detected Cryptosporidium in 24% of children with acute lymphoblastic leukemia (ALL) on maintenance chemotherapy, compared to 3% in control patients with diarrhoea (Hassanein et al., 2012) . In addition to being a cause of diarrhoea in oncology patients, Cryptosporidium has been associated with colon cancer (Sulżyc-Bielicka et al., 2013) and has been shown to induce low-tohigh grade intestinal dysplasia in immunocompromised mice (Abdou et al., 2013) .
Previous studies in Jordan (for which the immune status is unknown) have reported prevalences ranging from 1.5 -37.7% in humans and 3.9 -18.7% in production animals using both microscopy and molecular tools (Youssef et al., 2000; Nimri, 2003; Mahgoub et al., 2004; Hijjawi et al., 2010; Hijjawi et al., 2016 (. These differences likely reflect differences in detection methods, sample size, area of collection and microscopist skill etc.
During the present study, only one species, C. parvum and two gp60 subtypes (IIaA16G2R1, IIaA16G2R1), were detected in all the typed isolates. This was an unexpected finding as in two previous genotyping studies in Jordan, up to 4 Cryptosporidium species (C. parvum, C. hominis, C.
meleagridis, and C. canis) and six subtype families (IIa, IIc, IId, 1b, 1d and IIIa) were detected in human isolates (Hijjawi et al., 2010; Hijjawi et al., 2016) . In the previous two studies, C. parvum and C. hominis were the dominant species and were detected in almost equal frequencies (Hijjawi et al., 2010; Hijjawi et al., 2016) . The lack of identification of the C. parvum IId subtype and also C. A limitation of the present study is that while a compromised immune system can be assumed for the paediatric oncology patients, the immune status of non-oncology paediatric patients with diarrhoea is unknown, as this is not part of routine monitoring for children in Jordan hospitalised for diarrhoea. In addition, in the present study, the prevalence of Cryptosporidium species and subtypes in these children was accessed using microscopy only and therefore the true prevalence is likely underestimated. For example, one previous which compared microscopy and molecular analysis on Jordanian human patients identified a prevalence of 1.8% by microscopy and >19% by quantitative PCR (qPCR) confirming the superior sensitivity of PCR (Hijjawi et al., 2010) .
The finding of an additional 3 positives in the present study in the 30 microscopy negative samples, further supports this.
In conclusion, a high prevalence of cryptosporidiosis was detected amongst paediatric oncology patients. Routine screening for Cryptosporidium should be conducted for all oncology patients undergoing chemotherapy, preferably by PCR. The detection of cryptosporidiosis in these patients however presents specific challenges for the treatment, as the only FDA approved drug, nitazoxanide, is ineffective in immunocompromised individuals (Amadi et al., 2009) . A previous study reported the eradication of Cryptosporidium in four children with acute lymphoblastic leukemia using paromomycin or azithromycin (Trad et al., 2003) , and therefore these therapies should be considered for paediatric oncology patients. There is no vaccine for cryptosporidiosis and given the parasite's high infectivity, robustness, and resistance to disinfection , improved therapeutics particularly for immunocompromised individuals are urgently required. The advent of whole genome sequencing has identified several promising drug targets including inosine-5'-monophosphate dehydrogenase (IMPDH) (essential for purine salvage) and acyl-coenzyme A
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A C C E P T E D M A N U S C R I P T Table 2 Demographic data, Cryptosporidium species and subtypes for the 7 microscopy-positive faecal samples from non-oncology paediatric patients with diarrhea attending the Al-Mafraq paediatric hospital (all were from the Al-Mafraq area and surrounding villages). 
